PRQR250117P7500
- 0.00
- 0.000.00%
ProQR Therapeutics Newsroom
Chardan Capital Maintains ProQR Therapeutics(PRQR.US) With Buy Rating, Maintains Target Price $4
ProQR Therapeutics Is Maintained at Buy by Chardan Capital
H.C. Wainwright Maintains ProQR Therapeutics(PRQR.US) With Buy Rating, Maintains Target Price $10
ProQR Therapeutics Price Target Maintained With a $10.00/Share by HC Wainwright & Co.
ProQR Therapeutics Analyst Ratings
JMP Securities Maintains ProQR Therapeutics(PRQR.US) With Buy Rating, Maintains Target Price $8
JMP Securities Maintains ProQR Therapeutics(PRQR.US) With Buy Rating, Raises Target Price to $8
ProQR Therapeutics Analyst Ratings
H.C. Wainwright Maintains ProQR Therapeutics(PRQR.US) With Buy Rating, Raises Target Price to $10
Chardan Capital Maintains ProQR Therapeutics(PRQR.US) With Buy Rating, Announces Target Price $4
Raymond James Maintains ProQR Therapeutics(PRQR.US) With Buy Rating, Raises Target Price to $14
ProQR Therapeutics Analyst Ratings
ProQR Therapeutics Analyst Ratings
ProQR Therapeutics Analyst Ratings
ProQR Therapeutics Analyst Ratings
Chardan Capital Upgrades ProQR Therapeutics to Buy, Announces $2 Price Target
ProQR Therapeutics Analyst Ratings
Buy Rating for ProQR Therapeutics: Robust RNA-Editing Patent Portfolio, Promising Preclinical Candidates, and Strong Financial Position
Citigroup Maintains Buy on ProQR Therapeutics, Lowers Price Target to $1.8
ProQR Therapeutics Analyst Ratings